Several organizations have recognized our determination to help improve the lives of patients. We are honored by the work we do and by the recognition we receive.
Some of our most notable achievements include:
Prix Galien award:
IMBRUVICA® receives esteemed 2015 Prix Galien award for Best Pharmaceutical Agent, as voted on by a committee of 10 renowned leaders from the biomedical industry and academia.
In 2014, Pharmacyclics received BayBIO’s Pantheon DiNA™ Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA® (ibrutinib). BayBio is the northern California affiliate of the Biotechnology Industry Association (BIO). The award is determined through an independent nomination and selection process and presented to the one company each year that has made the greatest advancement in the life sciences industry in the region.
In 2012, Pharmacyclics and Janssen Biotech received the BayBIO Pantheon DiNA Award for Outstanding Partnering for the development and commercialization of IMBRUVICA® (ibrutinib).
National Organization for Rare Disorders (NORD):
In 2014, Pharmacyclics and Janssen Biotech received the NORD’s Partners in Progress Corporate Award for IMBRUVICA®(ibrutinib) for mantle cell lymphoma.
Society for Medicines Research:
In 2014, Pharmacyclics received the Society for Medicines Research Award for Drug Discovery. This independent research award recognizes outstanding development in the field of drug discovery, focusing on compounds that show a novel mechanism of action, a novel molecular interaction principle, a high degree of clinical benefit, and a significant ability to address an unmet medical need.
Web Marketing Association:
In 2014, Pharmacyclics and Janssen Biotech received the Web Marketing Association WebAward for Outstanding Achievement in Web Development for “The Storm From Within,” a website dedicated to education about B-cell malignancies.